Opus Genetics, Inc. Restricted Cash and Cash Equivalents
Opus Genetics, Inc. (IRD) had Restricted Cash and Cash Equivalents of $726.39 thousand as of 2012-06-30, per its 10-Q filed 2012-08-08.
Discontinued › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2012-11-08
- 2012-06-30: Restricted Cash and Cash Equivalents $726.39K.
- 2011-01-19: Restricted Cash and Cash Equivalents $179.67K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2012-06-30 | $726.39K 10-Q · filed 2012-08-08 |
| 2011-01-19 | $179.67K 10-Q · filed 2012-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |